CSD/BSE&NSE/PR/2023-2024
February 6, 2024

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA"**

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Digitally signed by Shrenik Soni
Date: 2024.02.06 11:06:47 +05'30'

Shrenik Soni
Company Secretary

Encl: as above

News Release

Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA

HYDERABAD, INDIA (6-Feb-2024) Suven Life Sciences announces the randomization of first patient in the Phase-2 clinical trial of Ropanicant (SUVN-911) for the treatment of moderate to severe Major Depressive Disorder (MDD) study in USA.

The trial is a multicenter, randomized, open-label, parallel-group study planned across 10 sites in the USA. The study will enroll approximately 36 patients who meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, (DSM-5) criteria for MDD without psychotic features and a diagnosis confirmed by the Mini-International Neuropsychiatric Interview (MINI). Patients will be randomized in a 1:1:1 ratio (12 patients in each treatment group) to receive ropanicant either 45 mg once a day, 30 mg twice a day, or 45 mg twice a day. Following a screening period of up to 4 weeks, the patients will be treated for 2 weeks.

The primary objective is to evaluate the safety and tolerability of ropanicant in patients with MDD. The secondary objective (efficacy objective) is to assess the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) total score at Week 2.

Topline data from the trial is expected to be available by Oct 2024. Additional information on the trial can be found at ClinicalTrials.gov Identifier NCT06126497.

About Ropanicant (SUVN-911): Ropanicant, a novel, potent, and selective α4β2 nAChR antagonist, is being developed for the treatment of MDD. Ropanicant has shown robust efficacy in various animal models of depression. Ropanicant addresses major limitations of current depressive disorder therapeutics by offering rapid onset of action, does not cause sexual dysfunction, and shows pro-cognitive effects. Ropanicant non-clinical safety has been established in various safety pharmacology and toxicity studies (up to 9-month duration). In the first in human study, ropanicant was tested in healthy subjects in two phase-1 studies (NCT03155503 and NCT03551288). It was well tolerated up to the highest tested dose in both single dose and multiple dose studies. No significant effect of food and age was noted on ropanicant pharmacokinetics. Ropanicant intellectual property rights are well protected in all major markets.

About Suven Life Sciences ("Suven"): Suven is a clinical-stage biopharmaceutical company, focused on discovering and developing novel pharmaceutical products, for CNS disorders. Our focus has been on the discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities. Suven singularly focuses on the development of "New Chemical Entities" ("NCEs") molecules for CNS diseases such as Alzheimer's, various forms of Dementia, Narcolepsy, Major Depressive Disorder ("MDD"), Attention Deficient Hyperactivity Disorder ("ADHD"), Huntington's disease, Parkinson, Bipolar disorder and different forms of neuropsychiatry disorders, gastrointestinal disorders, and pain disorders. Suven has 7 clinical-stage compounds, Masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 ongoing), Samelisant (SUVN-G3031) for sleep disorders (Phase-2 completed), Ropanicant (SUVN-911) for Major Depressive Disorder (Phase-2 ongoing) and Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 ready) and 3 other compounds in early stages of clinical development. In addition to clinical candidates, Suven has 8 molecules in the development pipeline.

For more information please visit our website at http://www.suven.com

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*